Equities research analysts predict that Verrica Pharmaceuticals Inc (NASDAQ:VRCA) will report earnings of ($0.25) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Verrica Pharmaceuticals’ earnings, with estimates ranging from ($0.25) to ($0.24). The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Verrica Pharmaceuticals will report full year earnings of ($1.15) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to ($0.75). For the next financial year, analysts forecast that the company will report earnings of ($1.01) per share, with EPS estimates ranging from ($1.21) to ($0.90). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Verrica Pharmaceuticals.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.76).
VRCA stock traded down $0.55 during midday trading on Wednesday, hitting $13.24. The company had a trading volume of 15,800 shares, compared to its average volume of 64,857. Verrica Pharmaceuticals has a 52 week low of $13.00 and a 52 week high of $23.29.
In other Verrica Pharmaceuticals news, Director Paul B. Manning bought 33,000 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was bought at an average price of $15.08 per share, for a total transaction of $497,640.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Linda Palczuk bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were acquired at an average price of $16.52 per share, with a total value of $41,300.00. The disclosure for this purchase can be found here. Insiders acquired 38,305 shares of company stock valued at $583,151 in the last quarter.
Several institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC bought a new position in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $29,195,000. Laurion Capital Management LP bought a new position in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $395,000. Fosun International Ltd bought a new position in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $15,705,000. FMR LLC bought a new position in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $21,703,000. Finally, Asymmetry Capital Management L.P. bought a new position in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $1,184,000. Institutional investors own 31.86% of the company’s stock.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals, Inc operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris.
Featured Article: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.